VKTX — Viking Therapeutics, Inc.

Viking Therapeutics (VKTX) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q3 2025 Financials:
  • Net Loss: $90.8 million ($0.81 per share), up from $24.9 million ($0.22 per share) in Q3 2024.
  • R&D Expenses: $90 million, significantly higher than $22.8 million in Q3 2024, driven by increased clinical study costs.
  • G&A Expenses: $8.6 million, down from $13.8 million in Q3 2024, due to reduced legal and patent expenses.
• Year-to-Date Financials (9 months):
  • Net Loss: $202 million ($1.80 per share), compared to $74.5 million ($0.69 per share) in the same period in 2024.
  • Cash Position: $715 million as of September 30, 2025, down from $903 million at year-end 2024.

2. Strategic Updates and Business Highlights

• Clinical Development:
  • VK2735: Advancing in obesity treatment with both oral and subcutaneous formulations.
  • Phase III VANQUISH Program: Ongoing trials for VK2735, with enrollment ahead of schedule. Expected completion by end of 2025 for VANQUISH-1 and Q1 2026 for VANQUISH-2.
  • Phase II VENTURE-Oral Dosing Study: Positive results reported, achieving primary and secondary endpoints with significant weight loss and favorable safety profile.
  • Maintenance Study Initiation: A new study to evaluate various maintenance dosing regimens for VK2735 has been initiated.

3. Forward Guidance and Outlook

• Viking anticipates continued high R&D spending as it progresses through Phase III trials and additional studies.
• Plans to submit an end of Phase II meeting request to the FDA for the oral formulation of VK2735, with hopes for clarity on next steps by year-end.
• The company is positioned to leverage its cash reserves to support ongoing and future clinical programs.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The substantial increase in net loss and R&D expenses raises concerns about financial sustainability, especially as the company ramps up clinical activities.
• Regulatory Risks: Potential delays in FDA communications due to the government shutdown could impact timelines for clinical meetings and approvals.
• Competitive Pressures: The oral GLP-1 space is experiencing high attrition rates, highlighting the challenges Viking may face in differentiating VK2735 from competitors.

5. Notable Q&A Insights

• Enrollment and Persistence: Early signs from the VANQUISH studies show no significant issues with patient persistence or discontinuation rates.
• Maintenance Study Details: The maintenance study will involve titration to various doses, with no auto-injector available for subcutaneous formulations.
• Future Studies: Discussions with payers regarding the importance of maintenance regimens indicate a strategic focus on demonstrating long-term benefits to enhance reimbursement prospects.
• Partnership Considerations: Viking remains open to partnerships for commercialization but is also prepared to proceed independently if necessary.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable insights from the Q&A, while also highlighting challenges and competitive pressures faced by Viking Therapeutics.